Joining the DoTS: New approach to classifying adverse drug reactions

British Medical Journal

Volumn 327, Issue 7425, 2003, Pages 1222-1225

  Aronson, Jeffrey K ^a   Ferner, Robin E ^b  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; CHLORAMPHENICOL; CLONIDINE; CORTICOSTEROID; DIETHYLSTILBESTROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR BLOCKING AGENT; HYPNOTIC SEDATIVE AGENT; ISONIAZID; LITHIUM; MEFLOQUINE; METHYLDOPA; MORPHINE; NEUROLEPTIC AGENT; NITRATE; PENICILLIN G; PHENYTOIN; QUININE; THALIDOMIDE; VANCOMYCIN;

ACUTE HEART INFARCTION; ADENOCARCINOMA; ALCOHOL INTOXICATION; ANAPHYLAXIS; COUGHING; DISEASE PREDISPOSITION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG SURVEILLANCE PROGRAM; GENETIC SUSCEPTIBILITY; HEADACHE; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPOTENSION; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; MALIGNANT HYPERTHERMIA; NEUTROPENIA; OSTEOPOROSIS; PHOCOMELIA; PORPHYRIA; PRIORITY JOURNAL; RASH; REVIEW; TARDIVE DYSKINESIA; THROMBOCYTOPENIA; THROMBOEMBOLISM; WITHDRAWAL SYNDROME;

EID: 0345257262     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.327.7425.1222     Document Type: Review

References (26)

1. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, ed. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1977:10.
2. Rawlins MD. Clinical pharmacology: adverse reactions to drugs. BMJ 1981;282:974-6.
3. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? The William Withering lecture 1994. J R Coll Phys Lond 1995;29:41-9.
4. Aronson JK. Drug therapy. In: Haslett C, Chilvers ER, Boon NA, Colledge NR, Hunter JAA, eds. Davidson's principles and practice of medicine 19th ed. Edinburgh: Elsevier Science, 2002:147-63.
5. Frenz DA. Interpreting atmospheric pollen counts for use in clinical allergy: allergic symptomology. Ann Allergy Asthma Immunol 2001;86:150-7.
6. Troisi CL, Heiberg DA, Hollinger FB. Normal immune response to hepatitis B vaccine in patients with Down's syndrome. A basis for immunization guidelines. JAMA 1985;254:3196-9,
7. Kelkar PS, Li JT. Cephalosporin allergy. N Engl J Med 2001;345:804-9.
8. Friedmann PS, Moss C, Shuster S, Simpson JM. Quantitative relationships between sensitising dose of DNCB and reactivity in normal subjects. Clin Exp Immunol 1983;53:709-15.
9. Wakelkamp M, Alvan G, Paintaud G. Natriuretic efficiency of frusemide as a consequence of drug input rate. Br J Clin Pharmacol 1997;43:481-91.
10. Pinkerton CR, Milla PJ. Methotrexate enterotoxicity: influence of drug dose and timing in the rat. Br J Cancer 1984;49:97-101.
11. Wallace MR, Mascola JR, Oldfield EC. Red man syndrome: incidence, etiology and prophylaxis. J Infect Dis 1991;164:1180-5.
12. Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. Ann Pharmacother 1996;30:55-61.
13. Saxon A, Beall GN, Rohr AS, Adelman DC. Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med 1987;107:204-15.
14. Geyman JP, Erickson S. The ampicillin rash as a diagnostic and management problem: case reports and literature review. J Fam Pract 1978;7:493-6.
15. Mulhall A, de Louvois J, Hurley R. Chloramphenicol toxicity in neonates: its incidence and prevention. BMJ 1983;287:1424-7.
16. Greenblatt DJ, Divoll M, Harmatz JS, MacLaughlin DS, Shader RI. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther 1981;30:475-86.
17. Schwartz E, Potasman I, Rotenberg M, Almog S, Sadetzki S. Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg 2001;65:189-92.
18. Batchelor JR, Welsh KI, Tinoco RM, Dollery CT, Hughes GR, Bernstein R, et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1980;i:1107-9.
19. Dickinson RG, Hooper WD, Wood B, Lander CM, Eadie MJ. The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin. Br J Clin Pharmacol 1989;28:17-27.
20. Aronson JK. Forbidden fruit. Nature Med 2001;7:7-8.
21. Clericetti N, Beretta-Piccoli C. Lithium clearance in patients with chronic renal diseases. Clin Nephrol 1991;36:281-9.
22. Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 1990;29:289-97.
23. Inman WHW, Mushin WW. Jaundice after repeated exposure to halothane: an analysis of reports to the Committee on Safety of Medicines. BMJ 1974;i:45-10.
24. Andréjak M, Gars V. Heparin. In: Dukes MNG, Aronson JK, eds. Meyler's side effects of drugs. 14th ed. Amsterdam: Elsevier, 2000:1177-8.
25. Yunis AA. Chloramphenicol toxicity: 25 years of research. Am J Med 1989;87:44-8N.
26. Roujeau J-C. Cutaneous reactions. In: Bénichou C, ed. Adverse drug reactions. A practical guide to diagnosis and management. Chichester: John Wiley, 1992:44-7.